Ευρωπαϊκή Ένωση - Αγγλικά - EMA (European Medicines Agency)

laboratorios hipra s.a. - inactivated bordetella bronchiseptica, strain 833cer / recombinant type-d pasteurella-multocida toxin (pmtr) - immunologicals - pigs (gilts and sows) - for the passive protection of piglets via colostrum after active immunisation of sows and gilts to reduce the clinical signs and lesions of progressive and non-progressive atrophic rhinitis, as well as to reduce weight loss associated with bordetella-bronchiseptica and pasteurella-multocida infections during the fattening period. challenge studies have demonstrated that passive immunity lasts until piglets are six weeks of age while in clinical field trials, the beneficial effects of vaccination (reduction in nasal lesion score and weight loss) are observed until slaughter.

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

international isotopes inc - sodium iodide i-131 (unii: 29vco8achh) (iodide ion i-131 - unii:4gc1foq22u) - sodium iodide i-131 solution is indicated for the treatment of hyperthyroidism and selected cases of thyroid carcinoma. sodium iodide i-131 is contraindicated in: - patients with vomiting and diarrhea [see warning and precautions (5.7)] . - patients with thyroid malignancies shown to have no iodide uptake, which include the majority of medullary or anaplastic carcinomas. - patients receiving concurrent anti-thyroid therapy [see warning and precautions (5.1) and drug interactions (7)] . - pregnancy [see warnings and precautions (5.4), see use in specific populations (8.1)] . - lactation [see warnings and precautions (5.5)] . risk summary sodium iodide i-131 is contraindicated in pregnancy because fetal exposure can lead to neonatal hypothyroidism, which in some cases is severe and irreversible [see warnings and precautions (5.4)] . data from the published literature describe thyroid abnormalities after fetal exposure; including agenesis of the thyroid and hypothyroidism (see data ). no animal reproductive studies have been conducted. clinical considerations . fetal/ neonatal adverse reactions a fetus exposed to sodium iodide i 131 can develop neonatal hypothyroidism. delay in diagnosis of neonatal hypothyroidism after exposure to sodium iodide i 131 in utero can result in severe sequelae such as decreased mental capacity and delayed bone age. monitor thyroid function in any infant born after in utero exposure to sodium iodide i 131. data human data sodium iodide i 131 crosses the placenta and the fetal thyroid begins to concentrate iodide during the 10-12 th week of gestation. in literature reports of maternal exposures to sodium iodide i 131 at doses of 333 – 8325 mbq (9 – 225 mci) during 4-26 weeks gestational age, the most common adverse outcomes were hypothyroid infants and children. risk summary sodium iodide i-131 solution is contraindicated during lactation because i-131 concentrates in the breast during lactation via the increased expression of the sodium iodide symporter in breast tissue and can lead to hypothyroidism in the infant through breastfeeding. if sodium iodide i-131 is administered postpartum, breastfeeding should not be restarted for the remainder of the postpartum period. in addition, to minimize the absorbed radiation dose to the breast tissue, breastfeeding and breast-pumping should be discontinued for at least 6 weeks before administration of sodium iodide i-131 [see warnings and precautions (5.5)] . infants exposed to sodium iodide i-131 through breast milk are at risk for development of hypothyroidism because sodium iodide i-131 is distributed into breast milk and may reach concentrations equal to or greater than concentrations in maternal plasma(see data ). data published literature describes sodium iodide i-131 transfer into breast milk and uptake by the thyroid of the breastfed infant. the amount of sodium iodide i-131 detected in the breast milk at 36 to 48 hours after administration is 1% to 27% of the injected dose (with injected doses between 1.1 mbq to 5,143 mbq). sodium iodide i-131 is contraindicated in pregnancy because of the risk of fetal hypothyroidism [see warnings and precautions (5.4) and [see use in specific populations (8.1)] . pregnancy testing obtain a pregnancy test in females of reproductive potential and verify the absence of pregnancy before initiating treatment [see dosage and administration (2.2) ]. contraception advise females and males of reproductive potential to use effective contraception during treatment with sodium iodide i-131 solution and for at least six months after the last dose of sodium iodide i-131 solution. infertility females fertility may be impaired with sodium iodide i-131 solution treatment. transient amenorrhea and ovarian insufficiency have been observed after sodium iodide i-131 therapy in females. the literature describes reports of transient menstrual cycle irregularities, including amenorrhea, and ovarian failure in females treated with cumulative doses of 1,000 mbq to 59,000 mbq (27 mci to 1,595 mci) sodium iodide i-131. in a published literature analysis, the effects on fertility occurred in up to 30% of women treated with sodium iodide i-131, and may resolve 12 months after treatment. males fertility may be impaired with sodium iodide i-131 solution treatment. discuss sperm banking for males who are expected to receive a high cumulative dose of sodium iodide i-131. transient dose-related impairment of testicular function after sodium iodide i-131 therapy has been reported in the published literature. the literature describes reports of males treated with sodium iodide i-131 at doses of 370 mbq to 22,000 mbq (10 mci to 595 mci) resulting in transiently impaired testicular function (including spermatogenesis). the risk of persistent testicular dysfunction increases after administration of repeated or high cumulative radioiodide exposure. the safety and effectiveness of sodium iodide i-131 solution have not been established in pediatric patients. pediatric patients are at an increased lifetime risk for malignancy from radiation exposure. clinical experience has not identified differences in safety or effectiveness in geriatric patients compared to younger patients. however, elderly patients are more likely to have decreased renal function and radiation exposure is greater in patients with impaired renal function [see use in specific populations (8.6), clinical pharmacology (12.3) ]. sodium iodide i 131 is primarily excreted by the kidneys. renal function impairment decreases excretion of sodium iodide i 131 and increases the radiation exposure and risk of radiation toxicity. for patients with a history of renal impairment, evaluate renal function for therapeutic planning and consider dosimetry. sodium iodide i 131 is dialyzable. hemodialysis can be used to reduce total body radiation exposure [see clinical pharmacology (12.3)].

Αυστραλία - Αγγλικά - APVMA (Australian Pesticides and Veterinary Medicines Authority)

abbey laboratories pty ltd - florfenicol - oral solution/suspension - florfenicol antibiotic active 23.0 g/l - antibiotic & related

Ισραήλ - Αγγλικά - Ministry of Health

unipharm ltd, israel - simvastatin - film coated tablets - simvastatin 20 mg - simvastatin - coronary heart disease : in patients with coronary heart disease and hypercholesterolemia simvacor is indicated to: reduce the risk of total mortality by reducing coronary death reduce the risk of non-fatal myocardial infarction reduce the risk for undergoing myocardial revascularization procedures.reduce the risk of stroke and transient ischemic attacks (tia).hyperlipidemia: simvacor is indicated as an adjunct to diet to reduce elevated total-c ldl-c apo b and tg and to increase hdl-c in patients with primary hypercholesterolemia( heterozygous familial and nonfamilial) and mixed dyslipidemia (frederickson types iia and iib) simvacor therefore lowers the ldl-c/hdl-c and the total-c/hdl-c ratios.homozygous familial hypercholesterolemia: simvacor is also indicated as an adjunct to diet and other non-dietary measures in reducing elevated total cholesterol ldl-cholesterol and apolipoprotein b in patients with homozygous familial hypercholesterolemia when response to these measures is inadequate. hypertriglyceridemia (fredrickson type iv hyperlipidemia). simvacor is indicated for the treatment of patients with primary dysbetalipoproteinemia (fredrickson type iii hyperlipidemia).

Ισραήλ - Αγγλικά - Ministry of Health

unipharm ltd, israel - simvastatin - film coated tablets - simvastatin 40 mg - simvastatin - coronary heart disease : in patients with coronary heart disease and hypercholesterolemia simvacor is indicated to: reduce the risk of total mortality by reducing coronary death reduce the risk of non-fatal myocardial infarction reduce the risk for undergoing myocardial revascularization procedures. reduce the risk of stroke and transient ischemic attacks (tia). hyperlipidemia: simvacor is indicated as an adjunct to diet to reduce elevated total-c ldl-c apo b and tg and to increase hdl-c in patients with primary hypercholesterolemia( heterozygous familial and nonfamilial) and mixed dyslipidemia (frederickson types iia and iib) simvacor therefore lowers the ldl-c/hdl-c and the total-c/hdl-c ratios.homozygous familial hypercholesterolemia: simvacor is also indicated as an adjunct to diet and other non-dietary measures in reducing elevated total cholesterol ldl-cholesterol and apolipoprotein b in patients with homozygous familial hypercholesterolemia when response to these measures is inadequate. hypertriglyceridemia (fredrickson type iv hyperlipidemia). simvacor is indicated for the treatment of patients with primary dysbetalipoproteinemia (fredrickson type iii hyperlipidemia). in patients at a high risk of coronary events because of existing coronary heart disease diabetes peripheral vessel disease history of stroke or other cerebrovascular disease simvacor is indicated to: - reduce the risk of total mortalily by reducing chd deaths. - reduce the risk of non-fatal myocardial infarction and stroke. - reduce the need for coronary and non-coronary revascularization procedures.

Ισραήλ - Αγγλικά - Ministry of Health

unipharm ltd, israel - simvastatin - film coated tablets - simvastatin 80 mg - simvastatin - coronary heart disease : in patients with coronary heart disease and hypercholesterolemia simvacor is indicated to: reduce the risk of total mortality by reducing coronary death reduce the risk of non-fatal myocardial infarction reduce the risk for undergoing myocardial revascularization procedures. reduce the risk of stroke and transient ischemic attacks (tia). hyperlipidemia: simvacor is indicated as an adjunct to diet to reduce elevated total-c ldl-c apo b and tg and to increase hdl-c in patients with primary hypercholesterolemia( heterozygous familial and nonfamilial) and mixed dyslipidemia (frederickson types iia and iib) simvacor therefore lowers the ldl-c/hdl-c and the total-c/hdl-c ratios. homozygous familial hypercholesterolemia: simvacor is also indicated as an adjunct to diet and other non-dietary measures in reducing elevated total cholesterol ldl-cholesterol and apolipoprotein b in patients with homozygous familial hypercholesterolemia when response to these measures is inadequate. hypertriglyceridemia (fredrickson type iv hyperlipidemia). simvacor is indicated for the treatment of patients with primary dysbetalipoproteinemia (fredrickson type iii hyperlipidemia). in patients at a high risk of coronary events because of existing coronary heart disease diabetes peripheral vessel disease history of stroke or other cerebrovascular disease simvacor is indicated to: - reduce the risk of total mortalily by reducing chd deaths. - reduce the risk of non-fatal myocardial infarction and stroke. - reduce the need for coronary and non-coronary revascularization procedures.

Μαλαισία - Αγγλικά - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

dksh malaysia sdn. bhd. - ripasudil hydrochloride hydrate -

Ισραήλ - Αγγλικά - Ministry of Health

dexcel ltd, israel - betamethasone as dipropionate; calcipotriol as monohydrate - cutaneous foam - betamethasone as dipropionate 0.5 mg / 1 g; calcipotriol as monohydrate 50 mcg / 1 g - calcipotriol, combinations - topical treatment of psoriasis vulgaris in adults

Ισραήλ - Αγγλικά - Ministry of Health

dexcel ltd, israel - betamethasone as dipropionate; calcipotriol as monohydrate - cutaneous foam - betamethasone as dipropionate 0.5 mg / 1 g; calcipotriol as monohydrate 50 mcg / 1 g - calcipotriol, combinations - topical treatment of psoriasis vulgaris in adults

Ιρλανδία - Αγγλικά - HPRA (Health Products Regulatory Authority)

ge healthcare as - iodixanol - solution for injection - 270 mg i/ millilitre(s) - watersoluble, nephrotropic, low osmolar x-ray contrast media; iodixanol